Global cardiac biomarkers market to reach USD 5893.8 million by 2026.

Global Cardiac Biomarkers Market Size study, by type (Myocardial muscle Creatine Kinase, Myoglobin, Troponins (T and I), Ischemia Modified Albumin (IMA), Brain Natriuretic Peptide (BNPs) or NT-proBNP and Others) Application (myocardial infarction, congestive heart failure, acute coronary syndrome, Atherosclerosis, other applications) Location of Testing (point of care testing and laboratory testing) and Regional Forecasts 2019-2026.
Product Code:  HALDAT_14605509
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Key Trends
1.3.	Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1.	Cardiac Biomarkers Market, by Type, 2016-2026 (USD Billion)
1.3.2.	Cardiac Biomarkers Market, by Application, 2016-2026 (USD Billion)
1.3.3.	Cardiac Biomarkers Market, by Location of testing, 2016-2026 (USD Billion)
1.3.4.	Cardiac Biomarkers Market, by Region, 2016-2026 (USD Billion)
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Cardiac Biomarkers Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Industry Evolution
2.2.2.	Scope of the Study
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Cardiac Biomarkers Market Dynamics	
3.1.	See Saw Analysis
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Cardiac Biomarkers Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Buyers
4.1.2.	Bargaining Power of Suppliers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model
4.2.	PEST Analysis
4.2.1.	Political Scenario
4.2.2.	Economic Scenario
4.2.3.	Social Scenario
4.2.4.	Technological Scenario
4.3.	Key Buying Criteria (On Demand)
4.4.	Regulatory Framework (On Demand)
4.5.	Investment Vs Adoption Scenario (On Demand)
4.6.	Analyst Recommendation & Conclusion
Chapter 5.	Global Cardiac Biomarkers Market, by Type 
5.1.	Market Snapshot 
5.2.	Market Performance - Potential Model
5.3.	Cardiac Biomarkers Market, Sub Segment Analysis
5.3.1.	  Myocardial muscle Creatine Kinase (CK-MB)     
5.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.	  Myoglobin
5.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.3.	   Troponins (T and I)
5.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.4.	 Ischemia Modified Albumin (IMA)
5.3.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.4.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.5.	  Brain Natriuretic Peptide (BNPs) or NT-proBNP      
5.3.5.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.5.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.6.	 Others      
5.3.6.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.6.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 6.	Global Cardiac Biomarkers Market, by Application          
6.1.	Market Snapshot 
6.2.	Market Performance - Potential Model
6.3.	Cardiac Biomarkers Market, Sub Segment Analysis
6.3.1.	  Congestive Heart Failure    
6.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.	  Myocardial Infarction
6.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.3.	  Atherosclerosis
6.3.4.	Acute Coronary Syndrome    
6.3.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.4.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.5.	 Other Cardiac Biomarkers 
6.3.5.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.5.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 7.	Global Cardiac Biomarkers Market, By Location Testing 
7.1.	Market Snapshot 
7.2.	Market Performance - Potential Model
7.3.	Global Cardiac Biomarkers Market, Sub Segment Analysis
7.3.1.	     Laboratory testing 
7.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion) 
7.3.2.	     Point of care testing 
7.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 8.	Global Cardiac Biomarkers Market, by Regional Analysis
8.1.	Cardiac Biomarkers Market, Regional Market Snapshot (2016-2026)
8.2.	North America Cardiac Biomarkers Market Snapshot
8.2.1.	U.S.
8.2.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.2.	 Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.2.1.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)  
8.2.1.4.	Location of testing breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.2.2.	Canada
8.2.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.2.2.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.2.2.4.	Location of testing breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.3.	  Europe Cardiac Biomarkers Market Snapshot
8.3.1.	U.K. 
8.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.3.1.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.3.1.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.3.2.	Rest of Europe
8.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.3.2.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.3.2.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.4.	Asia Cardiac Biomarkers Market Snapshot
8.4.1.	China 
8.4.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.1.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)  
8.4.1.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.4.2.	 India 
8.4.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.2.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.2.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.4.3.	Japan
8.4.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.3.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.3.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.4.4.	Rest of Asia Pacific
8.4.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.4.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.4.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.5.	Latin America Cardiac Biomarkers Market Snapshot
8.5.1.	Brazil 
8.5.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.5.1.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.5.1.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    

8.5.2.	Mexico 
8.5.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.5.2.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.5.2.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion)    
8.6.	Rest of The World 
8.6.1.	Middle East and Africa
8.6.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.2.	Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.6.1.3.	 Application breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.6.1.4.	Location of  testing  breakdown estimates & forecasts, 2016-2026 (USD Billion) 
Chapter 9.	Competitive Intelligence
9.1.	Company Market Share (Subject to Data Availability)
9.2.	Top Market Strategies
9.3.	Company Profiles
9.3.1.	 Concentra
9.3.1.1.	Overview
9.3.1.2.	Financial (Subject to Data Availability)
9.3.1.3.	Product Summary
9.3.1.4.	Recent Developments
9.3.2.	  Medexpress
9.3.3.	 American Family Care
9.3.4.	 Nextcare Holdings
9.3.5.	 Fastmed Urgent Care
9.3.6.	 Citymd
9.3.7.	 Carenow Urgent Care
9.3.8.	 Gohealth Urgent Care
9.3.9.	 HCA Healthcare UK
9.3.10.	 Columbia Asia Hospitals
Chapter 10.	Research Process
10.1.	Research Process
10.1.1.	Data Mining
10.1.2.	Analysis
10.1.3.	Market Estimation
10.1.4.	Validation
10.1.5.	Publishing
10.1.6.	Research Assumption

Global cardiac biomarkers market is valued at approximately USD 1475.5 million in 2018 and is anticipated to grow with a healthy growth rate of more than 18.9 % over the forecast period 2019-2026. Rising prevalence of cardiovascular diseases cost effective device, non-invasive method, accuracy in prediction, helpful in clinical trials, multi-application, increasing point of care application along with the technological advancements using cardiac biomarkers are some key trends that are responsible for the wide adoption of cardiac biomarkers globally.

Global cardiac biomarker market is majorly driven by rising prevalence of cardiovascular diseases. Cardiovascular diseases such as circulatory diseases, heart attacks and strokes are the leading cause for the premature death across the world. Cardiovascular diseases are caused by rising stress level and work pressure, harmful use of alcohol, unhealthy diet, obesity, tobacco use, and physical inactivity and it is most popular in aging population. Thus, cardiovascular diseases are the major cause of death across the globe. According the World Health Organization (WHO), in 2015 around 17.7million people died from cardiovascular diseases, signifying 31 % of global deaths, out of these 7.4million died due to coronary heart disease and 6.7 million died due to stroke across the world. As a result, the demand & adoption of cardiac biomarker would increase thereby, aiding the growth of the market over the forecast period of 2019-2026. Key market challenge for the global cardiac biomarker market is approval clinical validity and utility of biomarkers- based tests. However, to overcome this challenge the market also has various opportunities such as point of care testing using cardiac biomarkers, future developments in novel cardiac biomarkers and demand of personalized medicine.
On the basis of segmentation, the cardiac biomarkers market is segmented into type, application and location of testing. The type segment of global Cardiac Biomarkers market is classified into creatine Kinase (CK-MB), Troponins (T.I), myoglobin, Natriuretic Peptides (BNP & NT-PROBNP), ischemia modified albumin, others. Based on application segment the global cardiac biomarkers market is classified into myocardial infarction, congestive heart failure, acute coronary syndrome, Atherosclerosis, other applications of which myocardial infarction holds the highest share in the global cardiac biomarkers market due to high prevalence of cardiovascular diseases. The location of testing segment includes point of care testing and laboratory testing of which point of care accounts for the fastest growing segment due to clinicians and doctors mainly use point of care cardiac testing for quick testing and monitoring patients who are having chest pain.

The regional analysis of cardiac biomarkers market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America have occupied major share in the global cardiac biomarkers market. The major reasons for the dominance of North America are high CVD prevalence rates, high demand for cardiac testing and rising awareness towards cardiac diagnostics solutions. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific region is witnessed owing to rising affordability for the advanced cardiac treatments, modernization in the countries and increasing disposable income.
The leading market players include-

Roche Diagnostics
Abbott Laboratories,
Siemens Healthcare,
Alere Inc.,
Becton, Dickinson and Company,
Bio-Rad Laboratories,
BioMerieux,
Randox laboratories,
Beckman Coulter
Thermo Fisher Scientific

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Myocardial muscle Creatine Kinase (CK-MB)
Myoglobin
Troponins (T and I)
Ischemia Modified Albumin (IMA)
Brain Natriuretic Peptide (BNPs) or NT-proBNP
 Others
By Application:
Congestive Heart Failure
Myocardial Infarction
Atherosclerosis
Acute Coronary Syndrome
Others
By Location of testing:
Laboratory testing
Point of care testing
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
ROE
Asia Pacific
China
India
Japan
ROAPEC
LAMEA
Brazil
Mexico
ROW
Middle East & Africa

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Cardiac Biomarkers Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…